IPOGrid
0002070534
IPO filing research

SL Science Holding Ltd

Biological Products, (No Diagnostic Substances) · SLBT

ipo trading trading Nasdaq CERT

SL Science Holding Ltd IPO research page with SEC filing history, offering status, deal terms, structured filing extracts, company news, and comparable IPO context. Latest filing: CERT on 2026-06-12. Current deal snapshot: exchange Nasdaq.

Filing Timeline

SEC EDGAR
CERT inactive
CERT
Pre-IPO filing captured from the SEC submission timeline.
Follows 8-A12B in the pre-IPO sequence.
2026-06-12 · 0001354457-26-000569
8-A12B effective
Exchange Act registration
Registration filed to list the securities under the Exchange Act ahead of trading.
Follows 425 and registers the class of securities for exchange listing.
2026-06-11 · 0001213900-26-067818
425 supplemental
425
Pre-IPO filing captured from the SEC submission timeline.
Follows 425 in the pre-IPO sequence.
2026-03-24 · 0001213900-26-033584
425 supplemental
425
Pre-IPO filing captured from the SEC submission timeline.
Follows 425 in the pre-IPO sequence.
2026-02-18 · 0001213900-26-017662
425 supplemental
425
Pre-IPO filing captured from the SEC submission timeline.
Follows 425 in the pre-IPO sequence.
2026-02-06 · 0001213900-26-013231
425 supplemental
425
Pre-IPO filing captured from the SEC submission timeline.
Follows 425 in the pre-IPO sequence.
2026-02-03 · 0001213900-26-011285
425 supplemental
425
Pre-IPO filing captured from the SEC submission timeline.
Follows 425 in the pre-IPO sequence.
2026-01-30 · 0001213900-26-009873
425 supplemental
425
Pre-IPO filing captured from the SEC submission timeline.
Follows EFFECT in the pre-IPO sequence.
2026-01-15 · 0001213900-26-004683
EFFECT effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows 424B3 and marks the registration effective.
2026-01-13 · 9999999995-26-000155
424B3 priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows F-4/A and confirms the priced prospectus.
Ordinary · Exchange Nasdaq · Ticker SLBT · Use of proceeds To pay transaction expenses, provide operating capital, and meet Nasdaq listing requirements · Flags foreign_private_issuer, units
SL Science Holding Ltd's current IPO filing highlights significant regulatory challenges, particularly with the FDA, regarding its exosome and cell therapy products. The company faces uncertainty in obtaining U.S. market approval due to the complex, costly, and time-consuming FDA drug approval process. Exosome products are subject to heightened scrutiny, increasing the risk of regulatory delays or rejections. Cell therapy products, being novel, further complicate the pathway to market, with potential delays in clinical trials and approval. The filing emphasizes the risk of failure in clinical trials, regulatory non-approval, and potential consumer actions against its products.
2026-01-13 · 0001213900-26-003756
F-4/A amended
F-4/A
Pre-IPO filing captured from the SEC submission timeline.
Updates the prior F-4 filing.
Ordinary · Exchange Nasdaq · Ticker SLBT · Use of proceeds To finance transaction costs and working capital · Flags cayman_holding_company
2026-01-07 · 0001213900-26-001907
F-4 filed
F-4
Pre-IPO filing captured from the SEC submission timeline.
Follows DRS/A in the pre-IPO sequence.
Ordinary Shares of PubCo · Exchange Nasdaq Global Market · Ticker SLBT · Acquiror Units · Use of proceeds Debt repayment · Flags cayman_holding_company
2025-12-18 · 0001213900-25-122905
DRS/A amended
Amended draft registration statement
Updated draft registration filed before the public launch.
Updates the prior DRS/A filing.
2025-11-14 · 0001213900-25-110513
DRS/A amended
Amended draft registration statement
Updated draft registration filed before the public launch.
Updates the prior DRS/A filing.
2025-09-10 · 0001213900-25-086331
DRS/A amended
Amended draft registration statement
Updated draft registration filed before the public launch.
Updates the prior DRS filing.
2025-07-16 · 0001213900-25-064760
DRS filed
Draft registration statement
Draft registration filed confidentially before the public launch.
First tracked pre-IPO filing for this issuer.
2025-06-13 · 0001213900-25-054353
Comparable Deals

15 comparable deals

Healthcare & BiotechLast 18 months
Only 0 strict matches; expanded to 15 using nearest neighbors.
Showing top 8 by similarity.
+5.8%
Median day-1
53%
Above issue
-2.1%
Median week-1
-20.9%
Downside (p10)
Odyssey Therapeutics, Inc. ODTX
2026-05-08 $279M Day 1: -8.8% Wk 1: -3.8%
same SICrecent IPO
Hemab Therapeutics Holdings, Inc. COAG
2026-05-01 $302M Day 1: +88.9% Wk 1: +43.0%
same SICrecent IPO
Kardigan, Inc. KARD
2026-06-18 $400M Day 1: +37.5% Wk 1: +41.1%
same SIC grouprecent IPO
Agomab Therapeutics NV AGMB
2026-02-06 $200M Day 1: -8.4% Wk 1: -2.1%
same SICrecent IPO
Eikon Therapeutics, Inc. EIKN
2026-02-05 $381M Day 1: -16.7% Wk 1: -19.5%
same SICrecent IPO
Parabilis Medicines, Inc. PBLS
2026-06-10 $670M Day 1: +58.0% Wk 1: +30.2%
same SIC grouprecent IPO
Seaport Therapeutics, Inc. SPTX
2026-05-01 $255M Day 1: +10.2% Wk 1: -13.9%
same SIC grouprecent IPO
Avalyn Pharma Inc. AVLN
2026-04-30 $300M Day 1: +63.8% Wk 1: +53.9%
same SIC grouprecent IPO

Recent News

__symbol__ Stock Quote Price and Forecast | CNN
edition.cnn.com · 2026-06-14T21:02:00.000Z
SL BIO Ltd. and Horizon Space Acquisition II Announce Closing of Business Combination and Listing on the Nasdaq Global Market
markets.businessinsider.com · 2026-06-12T12:06:00.000Z